Heterotopic ossification: Pharmacologic options

Journal of Head Trauma Rehabilitation

Volumn 24, Issue 1, 2009, Pages 69-71

  Cullen, Nora ^a,c   Perera, Jerome ^b  

^a TORONTO REHABILITATION INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CALCIUM PHOSPHATE; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETIDRONIC ACID; HYDROXYAPATITE; INDOMETACIN; INTERLEUKIN 1; ISOENZYME; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCALCIN; PLACEBO; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; BONE DENSITY CONSERVATION AGENT;

ABDOMINAL DISTRESS; BONE INFECTION; BONE INJURY; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG WITHDRAWAL; DYSPEPSIA; ERYTHROCYTE SEDIMENTATION RATE; FRACTURE; GASTROINTESTINAL SYMPTOM; HETEROTOPIC OSSIFICATION; HUMAN; HYPERPHOSPHATEMIA; MESENCHYME CELL; MINERALIZATION; NAUSEA; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOMALACIA; RANGE OF MOTION; SEDATION; SHORT SURVEY; SPINAL CORD INJURY; STOMACH ULCER; TRAUMATIC BRAIN INJURY; BRAIN INJURY; METABOLISM; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BONE DENSITY CONSERVATION AGENTS; BRAIN INJURIES; DINOPROSTONE; ETIDRONIC ACID; HUMANS; OSSIFICATION, HETEROTOPIC;

EID: 66849113830     PISSN: 08859701     EISSN: None     Source Type: Journal    
DOI: 10.1097/HTR.0b013e31819a8fcc     Document Type: Short Survey

References (15)

1. Simonsen LL, Sonne-Holm S, Krasheninnikoff M, Engberg AW. Symptomatic heterotopic ossification after very severe traumatic brain injury in 114 patients: incidence and risk factors. Injury. 2007;38:1146-1150.
2. Hendricks HT, Geurts AC, van Ginneken BC, Heeren AJ, Vos PE. Brain injury severity and autonomic dysregulation accurately predict heterotopic ossification in patients with traumatic brain injury. Clin Rehabil. 2007;21:545-553.
3. Buschbacher R. Heterotopic ossification: a review. Clin Rev Phys Med Rehabil. 1992;4:199-213.
4. Vanden Bossche L, Vanderstraeten G. Heterotopic ossification: a review. J Rehabil Med. 2005;37:129-136.
5. Stover SL, Hataway CJ, Zeiger HE. Heterotopic ossification in spinal cord injured patients. Arch Phys Med Rehabil. 1975;56:199-204.
6. Macfarlane RJ, Ng BH, Gamie Z, et al. Pharmacological treatment of heterotopic ossification following hip and acetabular surgery. Expert Opin Pharmacother. 2008;9:767-786.
7. Vuolteenaho K, Moilanen T, Moilanen E. Non-steroidal antiinflammatory drugs, cyclooxygenase-2 and the bone healing process. Basic Clin Pharmacol Toxicol. 2008;102:10-14.
8. Banovac K, Williams JM, Patrick LD, Haniff YM. Prevention of heterotopic ossification after spinal cord injury with indomethacin. Spinal Cord. 2001;39:370-374.
9. van Kuijk AA, Geurts AC, van Kuppevelt HJ. Neurogenic heterotopic ossification in spinal cord injury. Spinal Cord. 2002;40:313-326.
10. Hu HP, Kuijpers W, Slooff TJ, van Horn JR, Versleyen DH. The effect of biphosphonate on induced heterotopic bone. Clin Orthop. 1991;272:259-267.
11. Mahay PR, Urist MR. Experimental heterotopic bone formation induced by bone morphogenic protein and recombinant human interleukin-1b. Clin Orthop. 1988;237:236-244.
12. Estrores IM, Harrington A, Banovac K. C-reactive protein and erythrocyte sedimentation rate in patients with heterotopic ossification after spinal cord injury. J Spinal Cord Med. 2004;27:434-437.
13. Sugita A, Hashimoto J, Maeda A, et al. Heterotopic ossification in bilateral knee and hip joints after long-term sedation. J Bone Miner Metab. 2005;23:329-332.
14. Haran M, Bhuta T, Lee B. Pharmacological interventions for treating acute heterotopic ossification. Cochrane Database Syst Rev. 2008;4.
15. Spielman G, Gennarelli TA, Rogers CR. Disodium etidronate: its role in preventing heterotopic ossification in severe head injury. Arch Phys Med Rehabil. 1983;64:539-542.